Literature DB >> 19067414

Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey.

David T Rubin1, Corey A Siegel, Sunanda V Kane, David G Binion, Remo Panaccione, Marla C Dubinsky, Edward V Loftus, Joseph Hopper.   

Abstract

BACKGROUND: Two national internet surveys were conducted to understand how patients perceive the impact of ulcerative colitis (UC) relative to gastroenterologists.
METHODS: In total, 451 patients with UC (20% mild, 63% moderate, 13% severe, 4% unsure [patient self-assessment]) were recruited for one survey and 300 gastroenterologists (not associated with the patients) were recruited for the other survey.
RESULTS: Patients reported, on average, 8 (self-defined) flares per year; this was more than the number anticipated by gastroenterologists. Sixty-two percent of patients with UC reported that their disease made it difficult to lead a normal life, compared with gastroenterologists' estimations of 36%. Only 42% of patients believed that being in remission could mean living without symptoms. Both patients and gastroenterologists reported that it is difficult for patients to take medication as prescribed every day (42% and 90%) and that managing UC medication is a struggle for patients (49% and 41%). Forty-six percent of patients admitted nonadherence to their therapy over the previous week, while gastroenterologists believed that 41% of their patients were not adherent.
CONCLUSIONS: These surveys identified disparities between patients' and gastroenterologists' perceptions of the impact of UC on patients' lives. The results suggest that more patients than gastroenterologists estimated chose to adapt their lives to accommodate UC rather than act to optimize therapy and adherence. Improved communication between patients and gastroenterologists, as well as better management strategies and education are necessary.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067414     DOI: 10.1002/ibd.20793

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  29 in total

Review 1.  Optimization of conventional therapy in patients with IBD.

Authors:  Kirstin M Taylor; Peter M Irving
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-10-04       Impact factor: 46.802

2.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Authors:  Sameer D Saini; Akbar K Waljee; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

3.  Inflammatory bowel disease: Appreciating disability and impact of disease.

Authors:  Subrata Ghosh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-03

4.  Fecal bacteriotherapy for ulcerative colitis: patients are ready, are we?

Authors:  Stacy A Kahn; Rita Gorawara-Bhat; David T Rubin
Journal:  Inflamm Bowel Dis       Date:  2011-05-25       Impact factor: 5.325

5.  Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.

Authors:  William J Sandborn; Jean-Frédéric Colombel; Subrata Ghosh; Bruce E Sands; Gerald Dryden; Xavier Hébuterne; Rupert W Leong; Brian Bressler; Thomas Ullman; Peter L Lakatos; Walter Reinisch; Li-An Xu; Allison Luo
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

6.  Perceived Emotional and Psychological Impact of Ulcerative Colitis on Outpatients in Spain: UC-LIFE Survey.

Authors:  Antonio López-Sanromán; Daniel Carpio; Xavier Calvet; Cristina Romero; Luis Cea-Calvo; Berta Juliá; Federico Argüelles-Arias
Journal:  Dig Dis Sci       Date:  2016-11-05       Impact factor: 3.199

7.  Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.

Authors:  Sunanda V Kane; Michael Sumner; Dory Solomon; Matthew Jenkins
Journal:  Dig Dis Sci       Date:  2011-08-31       Impact factor: 3.199

8.  Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale.

Authors:  Bijal Surti; Brennan Spiegel; Andrew Ippoliti; Eric A Vasiliauskas; Peter Simpson; David Q Shih; Stephan R Targan; Dermot P B McGovern; Gil Y Melmed
Journal:  Dig Dis Sci       Date:  2012-12-19       Impact factor: 3.199

9.  Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence.

Authors:  Steven J Bernick; Sunanda Kane
Journal:  Patient Relat Outcome Meas       Date:  2010-06-15

10.  Experiences of patients with chronic gastrointestinal conditions: in their own words.

Authors:  Jennifer B McCormick; Rachel R Hammer; Ruth M Farrell; Gail Geller; Katherine M James; Edward V Loftus; Mary Beth Mercer; Jon C Tilburt; Richard R Sharp
Journal:  Health Qual Life Outcomes       Date:  2012-03-08       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.